Table 2.
Survival Data | Treatment Arm |
|
---|---|---|
Erlotinib | BCNU/TMZ | |
Median PFS, months | 1.8 | 2.4 |
6-month PFS | ||
% | 11.4 | 24.1 |
95% CI* | 4.6 to 21.5 | |
1-year PFS, % | 5.7 | 4.0 |
Median OS, months | 7.7 | 7.3 |
6-month OS, % | 57.6 | 58.5 |
1-year OS, % | 21.9 | 26.7 |
Abbreviations: PFS, progression-free survival; OS, overall survival; BCNU, carmustine; TMZ, temozolomide.